This live roundtable discussion will center on the advancing field of bispecific antibodies in relapsed/refractory follicular lymphoma (R/R FL). This program will include a dynamic rapid-fire Q&A format. Experts in the field of follicular lymphoma will discuss clinical trial data, adverse event management, the current treatment landscape, and key differences between approved and emerging bispecific antibodies.
MODERATOR
Gilles Salles, MD, PhD
Professor of Medicine
Chief of the Lymphoma Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine
New York, New York
PANELIST
Matthew Lunning, DO, FACP
Associate Professor
Medical Director
Cellular Therapy
Associate Vice-Chair Research
Department of Medicine
Assistant Vice Chancellor for Clinical Research
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska
PANELIST
Joshua Brody, MD
Director
Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
New York, New York
6:15 pm
6:45 pm
6:50 pm
7:10 pm
7:25 pm
7:40 pm
720 S Michigan Ave, Chicago, Illinois, 60605
Room: International South
Upon completion of this activity, participants will:
Have increased knowledge regarding the
Have greater competence related to
Demonstrate greater confidence in their ability to
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded up to 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.
Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-144-L01-P).